The potential of the drug market for the treatment of diseases related to gastric acid secretion cannot be ignored, in recent years, with the acceleration of the pace of domestic life, changes in eating habits, etc.
, the incidence of gastrointestinal ulcers has increased year by year, and the market size of the drug has also been growing
.
Intranet data show that in 2017 in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) terminals, the sub-market size has exceeded 40 billion yuan, in recent years, although affected by the price reduction, the epidemic and other impacts, the scale has declined, but still maintained at more than
30 billion yuan.
In the face of considerable market space, more and more domestic pharmaceutical companies have entered the market to grab food, especially with the help of national procurement and medical insurance, domestic varieties have accelerated the grabbing of the original research market, and the market pattern has been continuously reshaped
.
For example, in the 2019 national medical insurance negotiation catalog, Livzon Group's eprazole sodium for injection was successfully shortlisted, and then the sales volume accelerated, with a growth rate of 780% in 2019, and sales revenue in 2021 exceeded 2 billion yuan
.
In the national collection, many varieties of drugs for the treatment of diseases related to gastric acid secretion have been won by domestic enterprises, such as in the aluminum magnesium carbonate market, in 2021, Chongqing Huasen Pharmaceutical won the bid, and Pfizer lost its qualifications; In the esomeprazole market, the original research AstraZeneca has not entered the collection, which has affected the continuous decline in
market share.
Recently, the list of drugs that have passed the preliminary examination of the 2022 medical insurance catalogue adjustment has been released, including a number of domestic drugs for the treatment of gastric acid secretion-related diseases that have passed the preliminary examination, such as Luoxin Pharmaceutical's Class 1 new drug Tigola raw tablets, Nanjing Haina Pharmaceutical's omeprazole sodium bicarbonate dry suspension (I) and omeprazole sodium bicarbonate dry suspension (II), etc.
Whether these varieties can successfully enter medical insurance is worth looking forward to in
the industry.
In addition, with the continuous efforts of domestic pharmaceutical companies, a large number of blockbuster new drugs have been declared for listing, which will bring impact to this 10 billion market, such as Xuanzhu Pharmaceutical's class 1 new drug analprazole sodium enteric-coated tablets, Xiamen Encheng Pharmaceutical's Esoprazole magnesium sodium bicarbonate capsules, Lansoprazole sodium bicarbonate capsules, and a large number of pharmacological companies grab the food of Osoprazole magnesium enteric-dried suspension and so on
.
Among them, analprazole sodium is a new generation of domestic independent research and development of proton pump inhibitors (PPI), July news, the new indications of the drug adult reflux esophagitis (RE) treatment and its related symptoms (acid reflux, heartburn, retrosternal pain or discomfort, belching reflux, etc.
) control of Phase II clinical trial application (IND) has been approved by
the State Food and Drug Administration of China.
Reflux esophagitis is a common disease of the digestive system, the incidence rate in the general population of China is as high as 6.
4%, and PPI is often used clinically for the treatment of reflux esophagitis, which has very significant clinical application value
.
Esomeprazole is the first hand autonator pump inhibitor (PPI), an S-isomer of omeprazole that blocks gastric acid secretion by specifically inhibiting H+-K+ATPase in gastric parietal cells
.
In 2007, esomeprazole magnesium enteric-coated dry suspension was approved for marketing in Sweden, followed by marketing in the United States, European countries and Japan, with three main indications
.
Among them, the US FDA approved the oral suspension of esomeprazole for the short-term treatment of gastroesophageal reflux disease in children aged 12 to 17 years and children aged 1 to 11 years, and is the first PPI preparation product
approved for pediatric clinical patients.
It is reported that Beimei Pharmaceutical and India Sipu Pharmaceutical cooperated on the product in October 2020, and the application for import imitation listing was undertaken by CDE in April 2021, and the product also has Chengdu Yuandong Biological, Aosaikang and other domestic pharmaceutical companies participating in the imitation, and it is also worth looking forward to
the future import of generic drugs and domestic generic drugs who will be the first to list.
